EP3565618A1 - Wearable non-liquid medication injection device - Google Patents
Wearable non-liquid medication injection deviceInfo
- Publication number
- EP3565618A1 EP3565618A1 EP18712708.9A EP18712708A EP3565618A1 EP 3565618 A1 EP3565618 A1 EP 3565618A1 EP 18712708 A EP18712708 A EP 18712708A EP 3565618 A1 EP3565618 A1 EP 3565618A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- chamber
- needle
- piston
- disposed
- medication
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229940079593 drug Drugs 0.000 title claims abstract description 107
- 239000003814 drug Substances 0.000 title claims abstract description 107
- 238000002347 injection Methods 0.000 title claims abstract description 39
- 239000007924 injection Substances 0.000 title claims abstract description 39
- 239000007788 liquid Substances 0.000 title claims abstract description 21
- 239000000126 substance Substances 0.000 claims abstract description 66
- 239000000463 material Substances 0.000 claims abstract description 63
- 238000000034 method Methods 0.000 claims abstract description 34
- 229920000642 polymer Polymers 0.000 claims description 25
- 238000010304 firing Methods 0.000 claims description 20
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 102000051325 Glucagon Human genes 0.000 claims description 15
- 108060003199 Glucagon Proteins 0.000 claims description 15
- 230000004913 activation Effects 0.000 claims description 15
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 15
- 229960004666 glucagon Drugs 0.000 claims description 15
- 230000004044 response Effects 0.000 claims description 13
- 239000003990 capacitor Substances 0.000 claims description 11
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 9
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 7
- 229960005139 epinephrine Drugs 0.000 claims description 7
- 239000012190 activator Substances 0.000 claims description 6
- 230000013011 mating Effects 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 238000009792 diffusion process Methods 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 230000032258 transport Effects 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 20
- 239000008103 glucose Substances 0.000 description 20
- 238000004891 communication Methods 0.000 description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 238000010999 medical injection Methods 0.000 description 9
- 238000003780 insertion Methods 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 238000002483 medication Methods 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000002218 hypoglycaemic effect Effects 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 206010002198 Anaphylactic reaction Diseases 0.000 description 5
- 230000036783 anaphylactic response Effects 0.000 description 5
- 208000003455 anaphylaxis Diseases 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000003380 propellant Substances 0.000 description 5
- 239000013543 active substance Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000008177 pharmaceutical agent Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000004590 computer program Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000003345 hyperglycaemic effect Effects 0.000 description 3
- 239000006193 liquid solution Substances 0.000 description 3
- 229910001000 nickel titanium Inorganic materials 0.000 description 3
- -1 polysiloxanes Polymers 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 2
- 239000004713 Cyclic olefin copolymer Substances 0.000 description 2
- 239000004812 Fluorinated ethylene propylene Substances 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 239000004696 Poly ether ether ketone Substances 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 229940015979 epipen Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229920009441 perflouroethylene propylene Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 229920002530 polyetherether ketone Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241001553178 Arachis glabrata Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 229920001774 Perfluoroether Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000006855 networking Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- UJMWVICAENGCRF-UHFFFAOYSA-N oxygen difluoride Chemical compound FOF UJMWVICAENGCRF-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0069—Devices for implanting pellets, e.g. markers or solid medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
- A61M5/155—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by gas introduced into the reservoir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/158—Needles for infusions; Accessories therefor, e.g. for inserting infusion needles, or for holding them on the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/19—Syringes having more than one chamber, e.g. including a manifold coupling two parallelly aligned syringes through separate channels to a common discharge assembly
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M5/2046—Media being expelled from injector by gas generation, e.g. explosive charge
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31525—Dosing
- A61M5/3153—Dosing by single stroke limiting means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/322—Retractable needles, i.e. disconnected from and withdrawn into the syringe barrel by the piston
- A61M5/3234—Fully automatic needle retraction, i.e. in which triggering of the needle does not require a deliberate action by the user
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3287—Accessories for bringing the needle into the body; Automatic needle insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
- A61M5/14248—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type
- A61M2005/14252—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type with needle insertion means
- A61M2005/14256—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body of the skin patch type with needle insertion means with means for preventing access to the needle after use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/158—Needles for infusions; Accessories therefor, e.g. for inserting infusion needles, or for holding them on the body
- A61M2005/1581—Right-angle needle-type devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/158—Needles for infusions; Accessories therefor, e.g. for inserting infusion needles, or for holding them on the body
- A61M2005/1585—Needle inserters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/2026—Semi-automatic, e.g. user activated piston is assisted by additional source of energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/206—With automatic needle insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/2086—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically having piston damping means, e.g. axially or rotationally acting retarders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0266—Shape memory materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/12—General characteristics of the apparatus with interchangeable cassettes forming partially or totally the fluid circuit
- A61M2205/123—General characteristics of the apparatus with interchangeable cassettes forming partially or totally the fluid circuit with incorporated reservoirs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3303—Using a biosensor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3546—Range
- A61M2205/3569—Range sublocal, e.g. between console and disposable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3576—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
- A61M2205/3592—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver using telemetric means, e.g. radio or optical transmission
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/82—Internal energy supply devices
- A61M2205/8206—Internal energy supply devices battery-operated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2209/00—Ancillary equipment
- A61M2209/08—Supports for equipment
- A61M2209/088—Supports for equipment on the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/201—Glucose concentration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M5/2066—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically comprising means for injection of two or more media, e.g. by mixing
Definitions
- the present disclosure relates to medication injection devices, and in particular to systems and methods for on-demand delivery of a non-liquid medication from a wearable medication injection device.
- Medical needles are widely used in the course of patient care and treatment, particularly with respect to the delivery of medication to a patient.
- hollow hypodermic needles are employed for
- transcutaneous delivery of a selected medication from a syringe or the like In another common form, insertion needles are employed for transcutaneous placement of a soft and relatively flexible tubular cannula, followed by insertion needle removal and subsequent infusion of medical fluid or medication to the patient through the cannula. For example, some people with diabetes may monitor their blood sugar to keep blood sugar levels as close to normal as possible without causing low blood sugar.
- Medications used to treat diabetes do so by lowering blood sugar levels.
- a person or health care provider may inject insulin, such as with a hypodermic needle or insertion needle for a tubular cannula, to help lower the blood sugar level.
- Epinephrine (adrenaline) is the primary treatment for anaphylaxis with no absolute contraindication to its use.
- the person or health care provider may inject epinephrine, such as with an off-the-shelf automated injector, e.g., an EpiPen®, to stop the anaphylaxis.
- an off-the-shelf automated injector e.g., an EpiPen®
- a major challenge to the on-demand delivery of the medication from the medication injection device is that the device needs to be worn, and should be able to maintain discreet footprint on the patient, i.e., a small overall size and low profile, in order to maintain customer satisfaction.
- many medications such as glucagon are typically stored as a 1 mL solution (liquid solution or dry-liquid mixture solution) in one or more chambers of the medication injection device, which takes up a significant portion of the overall size of the medication injection device. Therefore, the ability to minimize the space taken up by the storage of the medication, is important for the success of the wearable medication injection device.
- optimizing automated on-demand delivery of the medication is important for overall treatment of the medical condition and adoption of such a delivery device. Accordingly, the need exists for systems and methods that have the capability for automated on-demand delivery of a medication from a wearable medication injection device.
- One general aspect includes a device for injecting an injectable substance into a user, including: a housing defining a chamber having a first end and a second end.
- the device also includes a piston disposed towards the first end of the chamber and translatable within the chamber.
- the device also includes a hollow needle disposed within the chamber and extending from in front of the piston towards the second end of the chamber.
- the device also includes an energetic material disposed within the first end of the chamber and behind the piston to force the piston and hollow needle towards the second end of the chamber in response to activation of the energetic material.
- the device also includes a medication strip disposed within the hollow needle and including the injectable substance.
- Implementations may include one or more of the following features.
- the device where the medication strip includes one or more polymers and the injectable substance is in a non-liquid form that is at least one of: (i) disposed on a surface of the one or more polymers, and (ii) imbibed within the one or more polymers.
- the device further including a spring disposed within the chamber and extending from in front of the piston towards the second end of the chamber.
- the device further including a back hub attached to an end of the medication strip and disposed within the chamber and in front of the piston.
- the device further including a catch feature disposed at the second end of the chamber, where the catch feature includes a mating structure to engage and lock the back hub in place at the second end of the chamber once the piston is forced towards the second end of the chamber in response to activation of the energetic material.
- the device further including: an opening in the housing to an external environment.
- the device may also include a needle guide that defines a curved path that forces the hollow needle to bend towards the opening.
- Another general aspect includes a device for injecting an injectable substance into a user, including: a first portion including a firing circuit; and a second portion connected to the first portion.
- the second portion includes a chamber.
- the second portion also includes a piston disposed within the chamber.
- the second portion also includes a needle disposed within the chamber on a first side of the piston.
- the second portion also includes an energetic material disposed within the chamber on a second side of the piston and connected to the firing circuit.
- the second portion also includes a medication strip disposed within the needle, where the medication strip includes the injectable substance in a non-liquid form.
- Implementations may include one or more of the following features.
- the device where the first portion further includes a battery and one or more capacitors, the battery is configured to store a charge in one or more capacitors, and the firing circuit is configured to: (i) activate the energetic material by coupling the one or more capacitors to an activator in contact with the energetic material, and (ii) release the stored charge and initiate an exothermic reaction of the energetic material.
- the device where the injectable substance includes epinephrine or glucagon.
- the device further including a spring disposed within the chamber on the first side of the piston.
- the device further including a back hub attached to an end of the medication strip and disposed within the chamber on the first side of the piston.
- the device further including a catch feature disposed within the chamber on the first side of the piston, where the catch feature includes a mating structure to engage and lock the back hub in place once the piston is forced to traverse the chamber in response to activation of the energetic material.
- the device further including an opening in the second portion to an external environment.
- the device may also include a needle guide that defines a curved path that forces the needle to bend towards the opening, where the needle includes a hollow tube having one pointed end with an opening.
- Implementations of the described techniques may include hardware, a method or process, or computer software on a computer-accessible medium.
- a system of one or more computers can be configured to perform particular operations or actions by virtue of having software, firmware, hardware, or a
- One general aspect includes a method for delivering an injectable substance to a user, including receiving, at a first circuit, a command to deliver the injectable substance. The method also includes activating an energetic material disposed within a chamber of an injection device to initiate an exothermic reaction that forces a piston to traverse the chamber and drive a needle outside of the injection device into the user, where a medication strip is disposed within the needle and includes the injectable substance in a non-liquid form.
- the method also includes retracting the needle into the chamber from outside of the injection device, where the medication strip remains in the user upon retracting the needle.
- the method also includes delivering the injectable substance to the user.
- Other embodiments of this aspect include corresponding computer systems, apparatus, and computer programs recorded on one or more computer storage devices, each configured to perform the actions of the methods.
- Implementations may include one or more of the following features.
- the method where: the medication strip includes one or more polymers and the injectable substance is at least one of: (i) disposed on a surface of the one or more polymers, and (ii) imbibed within the one or more polymers.
- the method may also include the injectable substance is delivered to the user by way of passive diffusion of the injectable substance from the medication strip into the user.
- the method where initiating the exothermic reaction causes pressure to increase behind the piston, which eventually surpasses a force of a spring within the chamber, causing the spring to compress and the piston to traverse the chamber.
- the method where the retracting the needle includes releasing the pressure behind the piston such that when the force of the spring ultimately surpasses the pressure, the piston traverses the chamber causing the needle to retract into the chamber.
- the method where when the piston traverses the chamber and drives the needle outside of the injection device, the piston transports a back hub attached to an end of the medication strip through the chamber and into contact with a catch feature that engages the back hub, and engagement of the catch feature with the back hub allows for the medication strip to remain in the user upon retracting the needle. Implementations of the described techniques may include hardware, a method or process, or computer software on a computer-accessible medium.
- FIG. 1 shows a block diagram of a medical injection device in accordance with various embodiments
- FIG. 2 shows a block diagram of an example system for controlling a medical injection device in accordance with various embodiments
- FIGS. 3 A-3K show different views and phases of an example wearable medical injection device in accordance various embodiments.
- FIG. 4 shows an exemplary flow for delivering an injectable substance to a user with a wearable medical injection device in accordance with various embodiments.
- a problem associated with conventional medication injection devices is that they typically require some form of manual control (e.g., holding the device during injection), and the inject medications are typically stored as a bulky liquid solution. These limitations are detrimental to a fully autonomous medication injection device that can be worn by a user.
- various embodiments of systems and/or methods described herein are directed toward a connected wearable medication injection device that can inject a substance or medication on-demand in a non-liquid form such that a liquid solution is not necessary and the overall size and profile of the medication injection device may be decreased.
- the "injectable substance” or “medication” comprises any desired pharmaceutical agent or mixture of individual pharmaceutical agents or the like, for the administration of one or more active agents to a region of a patient.
- suitable injectable substances or medications may include epinephrine, glucagon or a glucagon activation solution, or other drugs or chemicals.
- non-liquid means a substance that is not a liquid.
- a non-liquid form may be a substance in a solid form, e.g., a dry powder medication.
- a medication injection device is a device or system having electronic circuit components and/or software configured to deliver the non-liquid substance to a specific site (e.g., a subdermal or subcutaneous) of the patient via an injectable needle.
- One or more portions of the medication injection device may be worn on a patient's body.
- a user with a medical condition such as diabetes or a severe allergy to a substance
- the user also the "wearer” obtains the device, which is about 20mm wide, about 25mm long, and about 1cm height.
- the example device has two halves that connect together to form a completed device.
- the first half may be disposable and has components to store and deliver a dose of an injectable substance, e.g., lmg of medication powder.
- the first half comprises a piston, a spring, an energetic material, and a hollow needle.
- a small detachable strip that is about lOOum in width, about 50um in thickness, and about 5mm in length and contains the injectable substance such as a dry form of a medication (as used herein when combined, a "medication strip”).
- the medication strip is held at the back end by a hub.
- the terms “substantially,” “approximately” and “about” are defined as being largely but not necessarily wholly what is specified (and include wholly what is specified) as understood by one of ordinary skill in the art. In any disclosed
- the term “substantially,” “approximately,” or “about” may be substituted with “within [a percentage] of what is specified, where the percentage includes 0.1, 1, 5, and 10 percent.
- the second half of the device includes circuitry to receive a command to inject the injectable substance and to activate the energetic material in response to the command.
- the wearer could press a button on the reusable half to trigger the circuitry to activate the charges.
- the circuitry could receive the command wirelessly from another device, such as the wearer's smartphone, continuous glucose monitor, a biosensor, insulin pump, etc.
- the circuitry is configured to activate the energetic material on-demand, for example in response to a signal received from a continuous glucose monitor.
- the energetic material may be activated by heating the energetic material, which causes a highly exothermic reaction that rapidly releases gas and heat.
- the spike in pressure from the exothermic reaction forces the piston towards the end of the device and drives the hollow needle and medication strip into the wearer.
- the needle and medication strip meet the end of travel, the needle is retracted via the spring, and the hub of the medication strip engages with a feature at an end of the device, forcing the medication strip to remain in place inside the wearer. While the medication strip is inside the wearer, the medication will passively elute into the wearer. When finished, the wearer may pull off the device, and the medication strip will naturally pull out with the device
- these approaches provide a medication injection device that has a small overall size and low profile, which is possible because the conventional liquid holding chambers are removed from the device and replaced with a medication strip that is stored in the hollow needle. Moreover, these approaches allow for on-demand medication delivery without user interaction (fully automated). Also advantageously, medications may be multiplexed on the medication strip to deliver "cocktails of active agents". For example, a portion of the strip may comprise glucagon and a second portion of the strip may comprise an activator for glucagon, which can be
- the medication strip described herein can make the medication injection device personalized to each individual patient.
- FIG. 1 shows a block diagram of a medical injection device 100 in accordance with various aspects.
- the device 100 includes two portions 105 and 110 that are connected, but are separable from each other.
- the first portion 105 comprises electronic components 115 that may be separable from the second portion 110 to allow for re-use of the electronics components 115.
- the second portion 110 comprises a chamber 120 that houses an injector comprising a needle 125 such as a hollow needle.
- the needle 125 comprises a hollow tube with a sharp tip at one end that contains a small opening (e.g., completely open, slotted, or partially opened) and a blunt tip at the other end that is either open or closed.
- the injector can be used to drive the needle 125 optionally through a needle cap 130 and into a user's skin.
- a detachable medication strip 135 that is about 15 ⁇ to 150 ⁇ in width, e.g., ⁇ in width, about 25 ⁇ to 75 ⁇ in thickness, e.g., about 50 ⁇ in thickness, and about 2.0mm to 7.5mm in length, e.g., 5mm in length, and contains the injectable substance such as a dry form of a
- the strip 135 is comprised of one or more polymers such as polysiloxanes, polytetrafluoroethylene (PTFE), polyether ether ketone (PEEK), polylactic acid (PLA), polyglycolic acid (PGA), polycaprolactone (PCL), polyethylene and cyclic olefin copolymers (COCs), perfluoroether (PFA), fluorinated ethylene propylene (FEP), polyimide, and polyesters.
- the injectable substance comprises any desired pharmaceutical agent or mixture of individual pharmaceutical agents or the like, for the administration of one or more active agents to a region of the user.
- suitable injectable substances or medications may include epinephrine, glucagon or a glucagon activation solution, or other drugs or chemicals.
- the injectable substance of the strip 135 is in a non-liquid form that is at least one of: (i) disposed on a surface of the one or more polymers, and (ii) imbibed within the one or more polymers.
- a medication may be immobilized onto a strip of polymer by depositing the injectable substance in liquid form onto a surface of the polymer and/or imbibing the injectable substance into the polymer to create an intermediate assembly (a polymer strip and injectable substance in liquid form), and the intermediate assembly is then freeze-dried using standard lyophilization methods to create a final assembly or medication strip (strip 135).
- the injectable substance may include a plurality of medications that are multiplexed on the medication strip to deliver "cocktails of active agents".
- a portion of the strip may comprise glucagon and a second portion of the strip may comprise an activator for glucagon, which can be
- the strip 135 can have various dosages and/or types of medications that are individualized for the user of the device 100, and thus make the device 100 personalized to the user.
- the strip 135 can be stored in the needle 125 within chamber 120. Upon actuation of the injection mechanism, the strip 135 is forced into the user via the needle 125. While the strip 135 is inside the wearer, the injectable substance may passively elute into the wearer. The second portion 110 may be discarded after delivering the injectable substance into the wearer.
- the device 100 is designed to be worn flush against a wearer's body, such as on an upper arm or torso.
- the height of the device 100 refers to how far the device 100 extends above the wearer's skin when worn.
- the length and width by contrast, refer to the dimensions of the perimeter of the device 100.
- the device 100 is about 15mm to 30mm wide, e.g., 20mm wide, about 15mm to 35mm long, e.g.,
- the needle 125 may be oriented to extend parallel to the wearer's skin; however, a needle guide 140 defines a curved path that forces the needle 125 to bend towards the wearer's skin at an angle departing from its initial orientation by approximately 30 degrees, 35 degrees, 40 degrees, or 45 degrees.
- the needle 125 is formed of a flexible material(s), such as a nickel -titanium alloy (e.g., Nitinol), to allow the needle 125 to bend at angles of up to 45 degrees (or more) without breaking or obstructing a travel path of the strip 135 through the interior of the needle 125.
- a nickel -titanium alloy e.g., Nitinol
- the needle 125 is a 22-gauge needle, 23-gauge needle, or a 25-gauge needle.
- a device size and needle size provide a mechanism suitable for injecting the strip 135 into the wearer while providing a device 100 that maintains a small size with a low profile and causes a tolerable amount of discomfort; however, other suitable device sizes and needle sizes and diameters may be employed.
- a housing 142 of the second portion 110 defines the chamber 120 that houses the injector.
- the injector may further comprise a piston 145 that is initially positioned at a first end of the chamber 120 opposite an opening 150 of the housing 142 to an external environment.
- the chamber 120 is in fluid communication to the opening 150.
- the chamber 120 is closed off from the opening 150 by the needle cap 130.
- the piston 145 is translatable within the chamber 120 (e.g., moveable from the first end towards a second end of the chamber).
- the needle 125 extends from in front of the piston 145 towards the second end of the chamber (the end near the opening 150).
- the piston 145 may be sized to have approximately the same cross-sectional area as the chamber 120 to prevent the contents of the chamber 120 from sliding around the piston 145 or, as described herein, gas pressure generated behind the piston 145 from being dissipated by escaping around the piston 145.
- the piston 145 has one or more seals attached around a perimeter of the piston 145 to prevent such leakage of material or gasses past the piston 145.
- the injector may further comprise an energetic material 155 (e.g., a propellant) disposed behind the piston 145 and connected to one or more of the electronic components 115 in the first portion 105.
- an energetic material 155 e.g., a propellant
- the energetic material 155 may undergo an exothermic reaction and generate pressure within a portion of the chamber
- the energetic material 155 comprises a nitrocellulose material.
- the energetic material 155 can be modified to create a faster-burning or slower-burning material based on device 100 design.
- the energetic material 155 may be a nitrocellulose material in a cotton-based format for faster-burning or in a paper-based format for a slower-burning format. Selection of an appropriate energetic material may be made based on size and constituents of the chamber 120, needle 125, strip 135, piston 145, and/or spring 160.
- the injector may further comprise the spring 160 disposed with in the chamber 120 and extending from in front of the piston 145 towards the second end of the chamber (the end near the opening 150). In some embodiments, the spring 160 abuts a front surface of the piston 145.
- the spring 160 may be provided (optionally coupled to the needle cap 130) to hold the piston 145 in place within the chamber 120 (e.g., abutting the energetic material 155) and enable retraction of the needle 125 once the energetic material 155 propels the piston 145 towards the second end of the chamber 120.
- the pressure generated by the energetic material 155 may initially overcome a force of the spring 160, but as the gasses from the exothermic reaction dissipate, e.g., via an exhaust port 167, the pressure within the chamber 120 drops and the spring 160 may ultimately overcome the pressure and retract the needle 125.
- the needle 125 and the strip 135 meet their end of travel into the wearer, the needle 125 is retracted via the spring 160.
- other needle retraction mechanisms may be employed, such as another propellant charge located beneath the needle cap 130.
- a back hub 165 is attached to an end of the strip 135 and initially disposed within the chamber 120 and in front of the piston 145. Additionally, a catch feature 170 is disposed at the second end of the chamber 120. The catch feature 170 includes a mating structure such as a clip to engage and lock the back hub 165 in the place at the second end of the chamber 120 once the piston 145 is forced towards the second end of the chamber 120 in response to activation of the energetic material 155. Attachment of the back hub 165 to the end of the strip 135 and the catch feature 170 allows for the strip 135 to remain in place inside the wearer during and after retraction of the needle 125.
- the first portion 110 includes components to receive a command (or commands) to initiate the exothermic reaction of the energetic material 155 and eventually drive the strip 135 into the wearer.
- the first portion 110 includes a firing circuit 175, a battery 180 or other electrical power source or connection, a wireless receiver 185, and an antenna 190.
- a command may be received via the antenna 190 and the receiver 185 from a remote device, such as the wearer's smartphone or a biosensor (e.g., a continuous glucose monitor), and the command may be relayed to the firing circuit 175.
- the firing circuit 175 may apply a signal, voltage, or current to the energetic material 155 using power supplied by the battery 180.
- the energetic material 155 is activated by an electrical discharge.
- the firing circuit 175 prior to receiving the command, charges one or more capacitors using the battery 180.
- the firing circuit 175 couples the capacitor(s), optionally in sequence, to an activator (e.g., electrical leads or a conductive contact) in contact with the energetic material 155, thereby allowing the capacitor(s) to discharge and initiate the exothermic reaction of the energetic material 155.
- an activator e.g., electrical leads or a conductive contact
- the firing circuit 175 battery 180, and receiver 185
- other electronic components may be provided within the first portion 110 as well, such as battery charging circuitry 192, power and filtering circuitry 195, and a microcontroller 197, e.g., an ASIC defined on a field-programmable gate array ("FPGA").
- FPGA field-programmable gate array
- Still further electronic components may be included within the first portion 110 to enable various features according to this disclosure. While the embodiments discussed herein employ a wireless command to activate the firing circuit 175, it should be understood that it has been contemplated that the device 100 may instead have a wired connection to another device, e.g., a biosensor, or may have a button or other wearer manipulatable device (“manipulandum”) to activate the firing circuit 175.
- FIG. 2 shows a block diagram of an example system 200 for controlling a medical injection device 205 (e.g., medical injection device 100 as discussed with respect to FIG. 1).
- a medical injection device 205 e.g., medical injection device 100 as discussed with respect to FIG. 1.
- the device 205 is in communication with a remote device 210 via communication link 215 such that at least the remote device 210 can send a signal and the device 205 can receive the signal (in other embodiments, both the device 205 and the remote device 210 can send and receive signals).
- the remote device 210 may be any suitable device with a wireless transmitter, such as a
- the communication link 215 may be any suitable wireless or wired means of
- the system 200 may include the device 205 and the remote device 210 within a distributed environment such as a cloud computing environment, and the device 205 and the remote device 210 may be in communication via one or more communication networks.
- Examples of communication networks include, without restriction, the Internet, a wide area network (WAN), a local area network (LAN), an Ethernet network, a public or private network, a wired network, a wireless network, and the like, and combinations thereof.
- the remote device 210 is a continuous glucose monitor that senses and stores glucose levels over time for the wearer.
- the glucose levels may be accessed wirelessly by various devices, such as the wearer's smartphone, an insulin pump, or example wearable drug injection devices according to this disclosure.
- the device 210 may be configured with one or more glucose level thresholds, below which the wearer is experiencing a hypoglycemic event and above which the wearer is experiencing a hyperglycemic event.
- the device 210 may periodically measure the wearer's glucose levels and compare them to the one or more glucose level thresholds. If a measured glucose level (or several consecutive measured glucose levels) exceeds one or more of the glucose level thresholds, the device 210 may determine a
- the device 210 may issue an alert to the wearer, such as by transmitting a signal to the wearer's insulin pump to trigger an audible alarm and, in the instance of a hyperglycemic event, trigger insulin delivery.
- the device 210 may also transmit a signal (e.g., a command signal) to the device 205 to cause the injection mechanism to deliver a dose of glucagon to the wearer.
- the device 210 may first transmit a signal to the wearer's insulin pump, if the wearer has one, and continue to monitor the wearer's glucose levels to detect whether the wearer's glucose levels continue to exceed one or more glucose level thresholds. If glucose levels do not continue to exceed one or more of the glucose level thresholds, then the device 210 may determine that appropriate action has been taken to alleviate the hypoglycemic event (e.g., the wearer has eaten something).
- the device 210 may then determine that intervention is needed and transmit the signal to the device 205 to cause a dose of glucagon to be injected into the wearer.
- a predetermined period of time e.g., 5 minutes
- the device 210 may then determine that intervention is needed and transmit the signal to the device 205 to cause a dose of glucagon to be injected into the wearer.
- Such an example may be desirable as it may allow the wearer to raise their glucose levels, even if they are unresponsive, e.g., due to being asleep or unconscious.
- other biosensors may be employed as well or instead for other pathologies and means for treatment. For example, blood pressure, electrocardiography, blood oxygen, etc.
- biosensors may be employed in some examples to detect medical events, such as anaphylaxis, etc., which may then trigger the biosensor, or another device such as a smartphone, to transmit a signal to the device 205 to cause an injectable substance, e.g., epinephrine, etc., to be injected into the wearer.
- medical events such as anaphylaxis, etc.
- another device such as a smartphone
- an injectable substance e.g., epinephrine, etc.
- FIGS. 3 A-3K show different views and phases of an example wearable medical injection device 300.
- FIG. 3A shows a disposable portion 305 (e.g., second portion 110 discussed with respect to FIG. 1) of the wearable medical injection device 300 that is connectable to a reusable portion (e.g., the first portion 105 discussed with respect to FIG. 1).
- the reusable portion may be releasably coupled to the disposable portion 305 by a connector 310.
- the connector 310 may comprise a plug and/or clips that engage with the reusable portion to releasably secure the disposable portion 305 and the reusable portion together.
- a housing 315 of the disposable portion 305 defines a chamber 320 comprising a piston 325 with one or more sealing rings 330, an energetic material 335, a spring 340, a needle 345, a medication strip 350, a back hub 355, a needle guide 360, and a catch feature 365.
- the chamber may have an opening 370 to allow the needle 345 and strip 350 to exit the device 300 by way of the needle guide 360, and an exhaust port 375 to allow gasses generated by the energetic material 335 to escape from the chamber 320. While FIG. 3A illustrates, the exhaust port 375 releases gasses directly into the wearer's environment, in some examples, the exhaust port 375 may vent exhaust gasses into a needle retraction mechanism.
- the energetic material 335 e.g., a propellant
- the piston 325 may be disposed behind the piston 325 and connected to one or more of the electronic components in the first portion via at least a portion of the connector 310 (e.g.,. conductive material of the connector).
- the spring 340 has a sufficient amount of force that it can hold the piston
- the spring 340 may be constructed from one or more materials such as iron, carbon, silicon, manganese, and chromium. The exact composition of the spring
- the 340 depends on the properties required for the device 300, which may include the loads the spring 340 will need to withstand, how many cycles of stresses and strain the spring
- the needle 345, the strip 350, and the back hub 355 may be disposed within the chamber 320.
- the back hub 355 is attached to an end of the strip
- the back hub 355 is not engaged with the catch feature
- the needle 345 may be attached to the piston 325 through an opening in the back hub 355.
- the needle 345 may be oriented in the chamber 320 to extend parallel to the wearer's skin; however, the needle guide 360 defines a curved path that forces at least a portion of the needle 345 to bend towards the wearer's skin (e.g., C-shaped bend) during the storage phase at an angle departing from its initial orientation by
- the needle 345 may be hollow to allow the strip 350 to be stored within the needle 345 and to be transported through the needle 345 into the wearer.
- the needle 345 comprises a hollow tube with a sharp tip at one end that contains an opening (e.g., completely open, slotted, or partially opened) and a blunt tip at the other end that is either open or closed.
- the opening in the needle 345 allows for the strip 350 to be loaded into the needle 345 (for storage) and for the strip 350 to be delivered to a user (injected into a user from within the needle 345).
- the needle 345 may be constructed from a flexible material, such as a suitable plastic or metallic material (e.g., Nitinol).
- the needle 345 in this example is sufficiently flexible that it can bend at an angle of between 25 to 45 degrees without permanently deforming and while maintaining an unimpeded path through the needle 345.
- the needle guide 360 as shown in FIGS. 3C-3H, is formed or coupled to the opening 370 to provide a path through which the needle 345 is forced to bend at an angle towards the wearer's skin.
- the needle 345 moves into and through the path formed in the needle guide 360 and bends towards the wearer's skin.
- the firing circuit Upon receiving the command signal from the receiver, the firing circuit activates the exothermic reaction of the energetic material 335 and the piston 325 is driven from the first end 380 of the chamber 320 to a second end 385 such that the needle 345 and strip 350 are driven out of the opening 370 into the wearer's skin.
- the needle 345 and the strip 350 are driven out of the opening 370 into the wearer's skin via the needle guide 360, and the back hub 355 remains attached to an end of the strip 350 but disposed at the second end 385 of the chamber 320. At this position, the back hub 355 is engaged with the catch feature 365.
- the catch feature 365 is a clip with two hooks for engaging a lip of the back hub 355, and thus holding the back hub 355 at the second end 385 of the chamber 320.
- the spring 340 is compressed at the second end 385 of the chamber 320 by the pressure generated by the exothermic reaction of the energetic material 335.
- the device 300 may retract the needle 345 via the spring 340.
- the pressure generated by the energetic material 335 may initially overcome a force of the spring 340, but as the pressure dissipates, e.g., via the exhaust port 375, the spring 340 may ultimately overcome the pressure and retract the needle 345.
- needle retraction mechanisms may be employed, such as another propellant charge located beneath a needle cap.
- the needle 345 is retracted back into the chamber 320 and the piston 325 may be positioned once more at the first end 380 of the chamber 320.
- the spring 340 has a sufficient amount of force that it can hold the piston 325 adjacent to the energetic material 335 at the first end 380 of the chamber 320 during the delivery phase.
- a first portion 390 of the strip 350 remains outside of the device and inside the wearer.
- a second portion 395 of the strip 350 remains attached to the back hub 355, which remains engaged with the catch feature 365, such that the strip 350 is not retracted with the needle 345.
- the injectable substance may passively elute into the wearer. Once the injectable substance has been delivered, the wearer may pull off the device 300, and the strip 350 will naturally pull out of the wearer due to the attachment of the strip 350 with the back hub 355 and the attachment of the back hub 355 with the housing 315 via the catch feature 365.
- FIG. 4 depicts a simplified flowchart depicting processing performed for delivering an injectable substance to a user according to various embodiments.
- the flowchart of FIG. 4 illustrates the architecture, functionality, and operation of possible implementations of systems, methods, and computer program products according to various embodiments of the present invention.
- each block in the flowchart or block diagrams may represent a module, segment, or portion of code, which comprises one or more executable instructions for implementing the specified logical functions.
- the functions noted in the block may occur out of the order noted in the figures.
- FIG. 4 depicts a simplified flowchart 400 illustrating a process for delivering an injectable substance to a user wearing an injection device. The process will be described with respect to the device 100 shown in FIG. 1 and the system shown in FIG. 2;
- the device 100 receives a command (or commands) to deliver an injectable substance.
- the device 100 receives the command from the remote device 210 via a BLE wireless activation signal.
- the remote device 210 may first establish a communications connection with the device 100, such as by pairing with the device using the BLE protocol and then authenticating itself to the device 100, e.g., by providing an encrypted communication comprising a digital signature or certificate.
- the remote device 210 transmits an activation signal, which may comprise the command.
- the remote device 210 authenticates itself to the device 100, such a feature is not required. Instead, the remote device 210 may simply transmit an activation signal, which may comprise the command, such as by broadcasting an activation signal.
- the device 100 activates the energetic material 155 to generate pressure and force the piston 145 towards an opposite end of chamber.
- the firing circuit 175 closes a switch to discharge a capacitor onto an activator in contact with the energetic material 155.
- the electrical discharge from the capacitor ignites the energetic material 155 and initiates the exothermic reaction.
- the exothermic reaction generates gasses that fill the chamber 120 and increase the pressure within the chamber 120 behind the piston 145.
- the pressure eventually surpasses a force of the spring 160, and the piston 145 traverses a portion of the chamber 120 forcing the needle 125 and detachable medication strip 135 through the needle guide 140, optionally the needle cap 130, and the opening 150 of the device 100. If a patient is wearing the device 100, the needle 125 and detachable medication strip 135 are injected into the wearer.
- the device 100 retracts the needle 125. If a patient is wearing the device 100, a portion of the medication strip 135 remains in the wearer during the retraction of the needle 125.
- the spring 160 is compressed by the movement of the piston 145 and pressure generated by the exothermic reaction. After a sufficient amount of the gasses dissipate, e.g., via an exhaust port 167, the spring 160 may ultimately overcome the pressure and retract the needle 125.
- other needle retraction mechanisms may be employed, such as another propellant charge located beneath the needle cap 130.
- the portion of the strip 135, which remained inside the wearer delivers the injectable substance to the wearer.
- the injectable substance may passively elute from the strip 135 into the wearer. Once the injectable substance has been delivered, the wearer may pull off the device 100, and the strip 135 will naturally pull out of the wearer due to the attachment of the strip 135 with the back hub 165 and the attachment of the back hub 165 with the housing 142 via the catch feature 170.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Environmental & Geological Engineering (AREA)
- Medical Informatics (AREA)
- Diabetes (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762444237P | 2017-01-09 | 2017-01-09 | |
US201762505457P | 2017-05-12 | 2017-05-12 | |
PCT/US2018/012940 WO2018129519A1 (en) | 2017-01-09 | 2018-01-09 | Wearable non-liquid medication injection device |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3565618A1 true EP3565618A1 (en) | 2019-11-13 |
Family
ID=70740349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18712708.9A Withdrawn EP3565618A1 (en) | 2017-01-09 | 2018-01-09 | Wearable non-liquid medication injection device |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3565618A1 (en) |
CN (1) | CN212662367U (en) |
WO (1) | WO2018129519A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE480278T1 (en) | 2005-09-12 | 2010-09-15 | Unomedical As | INTRODUCTION SYSTEM FOR AN INFUSION SET WITH A FIRST AND SECOND SPRING UNIT |
WO2012123274A1 (en) | 2011-03-14 | 2012-09-20 | Unomedical A/S | Inserter system with transport protection |
US11357912B2 (en) | 2016-01-19 | 2022-06-14 | Unomedical A/S | Cannula and infusion devices |
AU2020279722A1 (en) | 2019-05-20 | 2021-11-18 | Unomedical A/S | Rotatable infusion device and methods thereof |
WO2021007351A1 (en) * | 2019-07-10 | 2021-01-14 | Verily Life Sciences Llc | Pneumatic needle control |
WO2021007355A1 (en) * | 2019-07-10 | 2021-01-14 | Verily Life Sciences Llc | Systems and methods for wearable emergency drug injection devices |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4832682A (en) * | 1984-08-08 | 1989-05-23 | Survival Technology, Inc. | Injection method and apparatus with electrical blood absorbing stimulation |
BR0307589A (en) * | 2002-02-11 | 2005-02-01 | Antares Pharma Inc | Intradermal Injection Device |
GB0612020D0 (en) * | 2006-06-16 | 2006-07-26 | Brydges Price Richard I | Projectile for administering a medicament |
US20180021556A1 (en) * | 2015-02-13 | 2018-01-25 | Chee Yen Lim | Painless drug implanter |
-
2018
- 2018-01-09 CN CN201890000573.6U patent/CN212662367U/en active Active
- 2018-01-09 WO PCT/US2018/012940 patent/WO2018129519A1/en active Application Filing
- 2018-01-09 EP EP18712708.9A patent/EP3565618A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CN212662367U (en) | 2021-03-09 |
WO2018129519A1 (en) | 2018-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11565047B2 (en) | Wearable non-liquid medication injection device | |
CN212662367U (en) | Wearable non-liquid medicine injection device | |
JP7126540B2 (en) | Controllable drug delivery system and method of use | |
US11571164B2 (en) | Medical fluid injection apparatus and method with detachable patch and monitoring | |
JP6130377B2 (en) | Insertion mechanism for drug delivery pump | |
US20240057938A1 (en) | Medical fluid injection apparatus and method with detachable patch and monitoring | |
TW201742644A (en) | Drug delivery device, method of manufacture, and method of use | |
US20220176041A2 (en) | Self-contained auto-injector | |
US20230293108A1 (en) | Medical fluid injection apparatus and method with reusable patch | |
TWI690346B (en) | Injection device for administering a pharmaceutical agent | |
US20210353861A1 (en) | Wearable drug delivery device | |
US11712514B2 (en) | Cannulas for systems and methods for delivering microdoses of medication | |
US20230302264A1 (en) | Swallowable drug delivery devices | |
US11918778B2 (en) | Smart self-activating wearable device for automatically injecting medicines | |
US20240075202A1 (en) | Systems and methods for delivering microdoses of medication |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190724 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20220118 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230524 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20231005 |